Resverlogix Corp.

Locations:
  • Calgary, Alberta
- www.resverlogix.com/

Headcount: 35 employees

Industries:
  • Biotechnology
  • Healthcare Facility

Organization Profile

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

Contact Information

Bradd Cann
Chief Financial Officer
Tel: (403)254-9252
brad@resverlogix.com

Market Performance